Hereditary Transthyretin Amyloidosis (hATTR) is caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently result in instability of TTR and subsequent fibril formation. hATTR can be sub-classified into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The deposition of TTR amyloid fibrils in various tissues leads to ATTR, including Familial ATTR (hereditary ATTR) and non-hereditary ATTR types. Familial ATTR is a rare disorder with unequal distribution all around the world.
DelveInsight’s ‘Hereditary Transthyretin Amyloidosis (hATTR)- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Hereditary Transthyretin Amyloidosis (hATTR), historical and forecasted epidemiology as well as the hATTR market trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017–2030
Hereditary Transthyretin Amyloidosis (hATTR) Diagnosis
Disease heterogeneity and its rarity make a diagnosis of hATTR amyloidosis challenging. However, making a correct diagnosis is vital to determining prognosis, treatment, and appropriate patient and family counseling. Timely diagnosis is also important because it allows patients the opportunity to receive appropriate care as early as possible in the disease course.
Diagnosis can be confirmed via biopsy of the affected tissue or organ followed by staining with Congo red to confirm the presence of amyloid. The most sensitive test used for diagnosing cardiac involvement in hATTR amyloidosis is endomyocardial biopsy. However, it is not widely available. Therefore, other diagnostic tests are used for identifying cardiac involvement in hATTR amyloidosis, including electrocardiography (ECG), echocardiography, and cardiac magnetic resonance imaging (cMRI). Nuclear cardiology using scintigraphic tracers can also provide diagnostic value by allowing clinicians to visualize amyloid infiltration throughout the body.
Hereditary Transthyretin Amyloidosis (hATTR) Treatment
It covers the details of conventional and current medical therapies available in the Hereditary Transthyretin Amyloidosis (hATTR) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.
The DelveInsight Hereditary Transthyretin Amyloidosis (hATTR) market report gives a thorough understanding of Hereditary Transthyretin Amyloidosis (hATTR) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Hereditary Transthyretin Amyloidosis (hATTR) treatment algorithms and treatment guidelines for Hereditary Transthyretin Amyloidosis (hATTR) in the US, Europe, and Japan.
Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology
The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology division provide the insights about historical and current Hereditary Transthyretin Amyloidosis (hATTR) patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hereditary Transthyretin Amyloidosis (hATTR) Marketed Drugs
Vyndaqel/ Vyndamax: Pfizer
Vyndaqel (tafamidis meglumine 20 mg) and Vyndamax (tafamidis 61 mg) are oral transthyretin stabilizers that selectively bind to transthyretin, stabilizing the tetramer of the transthyretin transport protein and slowing the formation of amyloid. The tafamidis 61 mg capsule corresponds to an 80 mg tafamidis meglumine dose (4x 20mg capsules) and was developed for patient convenience to enable a single capsule for daily administration. Vyndamax 61 mg and Vyndaqel 20 mg are not substitutable on a per milligram basis.
Products detail in the report…
Hereditary Transthyretin Amyloidosis (hATTR) Market Outlook
The Hereditary Transthyretin Amyloidosis (hATTR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Transthyretin Amyloidosis (hATTR) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, Hereditary Transthyretin Amyloidosis (hATTR) market in 7MM is expected to change in the study period 2017–2030.
Hereditary Transthyretin Amyloidosis (hATTR) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis (hATTR) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Hereditary Transthyretin Amyloidosis (hATTR) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Scope of the Report
- The report covers the descriptive overview of Hereditary Transthyretin Amyloidosis (hATTR), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
- Comprehensive insight has been provided into the Hereditary Transthyretin Amyloidosis (hATTR) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hereditary Transthyretin Amyloidosis (hATTR) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Hereditary Transthyretin Amyloidosis (hATTR) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hereditary Transthyretin Amyloidosis (hATTR) market
Table of contents:
1 Key Insights
2 Executive Summary of hATTR
3 Hereditary Transthyretin Amyloidosis Market Overview at a Glance
4 Hereditary Transthyretin Amyloidosis (hATTR): Disease Background and Overview
5 Epidemiology and Patient Population
6 Current Treatment and Medical Practices
7 Unmet Needs
8 Marketed Drugs
8.1 Key Cross Competition
8.2 Vyndaqel/ Vyndamax: Pfizer
8.3 Onpattro: Alnylam Pharmaceuticals
8.4 Tegsedi: Akcea Therapeutics/ Ionis Pharmaceuticals
9 Emerging Therapies
9.1 Key Cross Competition
10 Phase III and Filed Drugs
10.1 Vutrisiran: Alnylam Pharmaceuticals
10.1.1 Product Description
10.1.2 Research and development
10.1.3 Product Development Activities
10.2 AKCEA-TTR-LRx: Ionis Pharmaceuticals
10.2.1 Product Description
10.2.2 Research and development
10.2.3 Product Development Activities
10.3 AG 10: Eidos Therapeutics
10.3.1 Product Description
10.3.2 Research and development
10.3.3 Product Development Activities
11 Phase II Drugs
11.1 CRX-1008: Corino Therapeutics Inc
11.1.1 Product Description
11.1.2 Research and development
11.1.3 Product Development Activities
12 Phase I Drugs
12.1 PRX004: Prothena
12.1.1 Product Description
12.1.2 Research and development
13 Hereditary Transthyretin Amyloidosis: Market Analysis
13.1 Key Findings
14 Hereditary Transthyretin Amyloidosis (hATTR) Market Outlook
15 Market Drivers
16 Market Barriers
17 Reimbursement Scenario
18 Patient Support Programs
18.1 Vyndaqel/ Vyndamax:
19 SWOT Analysis
20 KOL’s Views
21.2 Report Methodology
22 DelveInsight Capabilities
24 About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States